A Dual Disease State TAVR SolutionJenaValve is a clinical-stage medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of both severe aortic regurgitation and stenosis. JenaValve is passionate about providing our physician partners with cutting edge technology aimed at improving the lives of our patients. […]
Location: Germany
Employees: 11-50
Total raised: $212.5M
Investors 3
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
| - | Andera Par... | anderapart... |
| 16.06.2022 | GIMV | gimv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 31.08.2022 | - | $100M | - |
| 05.02.2020 | - | $50M | - |
| 23.07.2013 | - | $62.5M | - |
Mentions in press and media 6
| Date | Title | Description |
| 26.07.2024 | Andera Partners Co-Leads $196 Million Round for Kestra Medical and Welcomes Raymond W. Cohen to Board of Directors | Kestra Medical is an American company also present in Ireland, which has developed and commercializes a medical device: a vest equipped with a portable defibrillator for patients at risk of sudden cardiac arrest. The $196 million financing ... |
| 25.07.2024 | Andera Partners’ portfolio company JenaValve Technology acquired by Edwards Lifesciences | Andera Partners, a leading European private equity player, announced today that its portfolio company, JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), will be acquired by Edwards Lifesciences, a ... |
| 31.08.2022 | JenaValve Raises $100 Million to Advance Trilogy TAVR Solution | JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has completed the initial closing of a $100 million Series... |
| 05.02.2020 | JenaValve Technology Closes $50 Million Financing | JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financ... |
| 23.07.2013 | JenaValve raises $62.5 Million in Venture Funding - Capital to Fund Clinical Study for Transfemoral TAVI system, Expansion of Commercial Initiatives | JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has raised $62.5 ... |
| 24.09.2007 | Life sciences briefing: Monday, Sept. 24, 2007 | Featured companies: Adnexus Therapeutics, Bristol-Myers Squibb, Cellerix, Elixir Therapeutics, GenomeQuest, Intronn, JapanBridge, JenaValve, VirXsys, Ysios Capital [NOTE: This item is a catchup daily briefing originally posted on 9/27/07. I... |